Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives (original) (raw)

Pulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary Fibrosis

American Journal of Respiratory Cell and Molecular Biology, 2012

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis

JAMA

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary ...

Line Oste

Journal of Medicinal Chemistry

View PDFchevron_right

Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities

Darcey Black

Drug Discovery Today, 2020

View PDFchevron_right

Autotaxin in Pathophysiology and Pulmonary Fibrosis

Christiana Magkrioti

Frontiers in Medicine, 2018

View PDFchevron_right

Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis

Nikolaos Siafakas

Pulmonary Pharmacology & Therapeutics, 2007

View PDFchevron_right

Emerging drugs for idiopathic pulmonary fibrosis

Robert Hyzy

Expert Opinion on Emerging Drugs, 2011

View PDFchevron_right

Discovery of Highly Selective and Orally Active Lysophosphatidic Acid Receptor-1 Antagonists with Potent Activity on Human Lung Fibroblasts

MARIA CARMEN FERNÁNDEZ FUENTES

Journal of Medicinal Chemistry, 2012

View PDFchevron_right

Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis

Lance Goulet

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016

View PDFchevron_right

Current and novel drug therapies for idiopathic pulmonary fibrosis

Huzaifa Adamali

Drug Design, Development and Therapy, 2012

View PDFchevron_right

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA₁) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases

Ramesh Babu Reddigunta

Journal of Medicinal Chemistry, 2021

View PDFchevron_right

Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options

Monica Deleon

Expert Opinion on Pharmacotherapy, 2020

View PDFchevron_right

Selective Inhibition of Autotaxin is Efficacious in Mouse Models of Liver Fibrosis

Lance Goulet

The Journal of pharmacology and experimental therapeutics, 2016

View PDFchevron_right

Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?

Tracy Luckhardt

Drugs, 2016

View PDFchevron_right

Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future

George Margaritopoulos

European Respiratory Review, 2013

View PDFchevron_right

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis

Ganesh Raghu

European Respiratory Review, 2019

View PDFchevron_right

Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential

Ganesh Raghu

European Respiratory Review, 2017

View PDFchevron_right

The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak

Andrew Tager

Nature Medicine, 2008

View PDFchevron_right

Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence

Miguel Bergna

European Respiratory Review, 2018

View PDFchevron_right

Idiopathic Pulmonary Fibrosis: Molecular Mechanisms and Possible Therapeutic Strategies

Maikel Peppelenbosch

Inflammation, 2001

View PDFchevron_right

New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing Responses

Andrew Tager

American Journal of Respiratory and Critical Care Medicine, 2014

View PDFchevron_right

A Refined Approach to Target the Molecular and Cellular Mechanisms in Pulmonary Fibrosis

Archita Ray

Targeting Cellular Signalling Pathways in Lung Diseases, 2021

View PDFchevron_right

Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives (original) (raw)

Related papers